VIA
ENTA icon

Vident Investment Advisory’s Enanta Pharmaceuticals ENTA Stock Holding History

Vident Investment Advisory’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-15,450
Closed -$558K – 516
2015
Q3 		$558K Buy
+15,450
New +$663K 0.08% 474

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vident Investment Advisory's ENTA Position: Q4 2015 in Review

Vident Investment Advisory sold out of Enanta Pharmaceuticals (ENTA) in Q4 2015, closing a stake of 15,450 shares — an estimated $558K sold.

Vident Investment Advisory first reported a position in ENTA in Q3 2015 and held it in 1 quarter. The position peaked at $558K in Q3 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q4 2015.

  • Vident Investment Advisory reported no remaining Enanta Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Vident Investment Advisory sold 15,450 Enanta Pharmaceuticals shares in Q4 2015, an estimated $558K.
  • Vident Investment Advisory first reported a position in Enanta Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Vident Investment Advisory's Enanta Pharmaceuticals position peaked at $558K in Q3 2015.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2015.

Based on Vident Investment Advisory's 13F filing for Q4 2015, filed 17 Feb 2016.